Novo Nordisk owner refiles U.S. application for approval of Catalent deal
08/04/2024 10:55
COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom) ((stine.jacobsen@thomsonreuters.com; +45 21 56 90 10;))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled